Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.

Autor: Suntsova EV; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Maschan AA; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Baydildina DD; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Kalinina II; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Petrova UN; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Pshonkin AV; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia., Novichkova GA; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2019 Jun; Vol. 66 (6), pp. e27704. Date of Electronic Publication: 2019 Mar 11.
DOI: 10.1002/pbc.27704
Abstrakt: We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2-15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 10 9 /L at 13-39 months after switching.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: